Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Pamiparib (BGB-290) Plus Temozolomide for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)

NCT04603365 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04603365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04603365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Pamiparib (BGB-290) Plus Temozolomide for Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
October 18, 2021
Completion date
May 7, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell papillary renal neoplasm, collecting duct carcinoma, hereditary leiomyomatosis and renal cell carcinoma, hereditary papillary renal cell carcinoma, metastatic renal cell carcinoma, metastatic unclassified renal cell carcinoma, papillary renal cell carcinoma, stage iii renal cell cancer american joint committee on cancer (ajcc) v8, stage iv renal cell cancer ajcc v8, tubulocystic renal cell carcinoma, unresectable renal cell carcinoma